Moyes et al. evaluated the incidence of usual myeloid markers like CD163, CD68, and CD33, as well as S100A9 using quantitatively analyzed tissue microarrays made of samples taken from grades I-III astrocytoma's and GBM [54]. This evidence concerns the gene CD68 and glioblastoma.